Ha H, Gonzalez A (2019) Migraine headache prophylaxis. Am Fam Physician 99(1):17–24

PubMed  Google Scholar 

Burstein R, Zhang X, Levy D, Aoki KR, Brin MF (2014) Selective inhibition of meningeal nociceptors by botulinum neurotoxin type A: therapeutic implications for migraine and other pains. Cephalalgia 34:853–869. https://doi.org/10.1177/0333102414527648

Article  PubMed  PubMed Central  Google Scholar 

Zhang X, Strassman AM, Novack V, Brin MF, Burstein R (2016) Extracranial injections of botulinum neurotoxin type A inhibit intracranial meningeal nociceptors’ responses to stimulation of TRPV1 and TRPA1 channels: are we getting closer to solving this puzzle? Cephalalgia 36:875–886. https://doi.org/10.1177/0333102416636843

Article  CAS  PubMed  PubMed Central  Google Scholar 

Waliszewska-Prosół M, Vuralli D, Martelletti P (2023) What to do with non-responders to CGRP(r) monoclonal antibodies: switch to another or move to gepants? J Headache Pain 24(1):163. https://doi.org/10.1186/s10194-023-01698-8

Article  PubMed  PubMed Central  Google Scholar 

Evers S, Afra J, Frese A, Goadsby PJ, Linde M, May A et al (2009) European Federation of Neurological Societies. EFNS guideline on the drug treatment of migraine–revised report of an EFNS task force. Eur J Neurol 16(9):968–981. https://doi.org/10.1111/j.1468-1331.2009.02748.x

Article  CAS  PubMed  Google Scholar 

Versijpt J, Deligianni C, Hussain M, Amin F, Reuter U, Sanchez-Del-Rio M et al (2024) European Headache Federation (EHF) critical re-appraisal and meta-analysis of oral drugs in migraine prevention - part 4: propranolol. J Headache Pain 25(1):119. https://doi.org/10.1186/s10194-023-01573-6

Article  CAS  PubMed  PubMed Central  Google Scholar 

Sprenger T, Viana M, Tassorelli C (2018) Current prophylactic medications for migraine and their potential mechanisms of action. Neurotherapeutics 15(2):313–323. https://doi.org/10.1007/s13311-018-0621-8

Article  CAS  PubMed  PubMed Central  Google Scholar 

al-Qassab HK, Findley LJ (1993) Comparison of propranolol LA 80 mg and propranolol LA 160 mg in migraine prophylaxis: a placebo controlled study. Cephalalgia 13(2):128–131. https://doi.org/10.1046/j.1468-2982.1993.1302128.x

Article  CAS  PubMed  Google Scholar 

Tronvik E, Stovner LJ, Helde G, Sand T, Bovim G (2003) Prophylactic treatment of migraine with an angiotensin II receptor blocker: a randomized controlled trial. JAMA 289(1):65–69. https://doi.org/10.1001/jama.289.1.65

Article  CAS  PubMed  Google Scholar 

Stovner LJ, Linde M, Gravdahl GB, Tronvik E, Aamodt AH, Sand T et al (2014) A comparative study of candesartan versus propranolol for migraine prophylaxis: a randomised, triple-blind, placebo-controlled, double cross-over study. Cephalalgia 34(7):523–532. https://doi.org/10.1177/0333102413515348

Article  PubMed  Google Scholar 

Messina R, Lastarria Perez CP, Filippi M, Goadsby PJ (2020) Candesartan in migraine prevention: results from a retrospective real-world study. J Neurol 267(11):3243–3247. https://doi.org/10.1007/s00415-020-09989-9

Article  CAS  PubMed  Google Scholar 

Sánchez-Rodríguez C, Sierra Á, Planchuelo-Gómez Á, Martínez-Pías E, Guerrero ÁL, García-Azorín D (2021) Real world effectiveness and tolerability of candesartan in the treatment of migraine: a retrospective cohort study. Sci Rep 11(1):3846. https://doi.org/10.1038/s41598-021-83508-2

Article  CAS  PubMed  PubMed Central  Google Scholar 

García-Azorín D, Martínez-Badillo C, Camiña Muñiz J, Gago-Veiga AB, Morollón Sánchez N, González-Quintanilla V et al (2024) CandeSpartan Study: Candesartan Spanish response-prediction and tolerability study in migraine. Cephalalgia 44(4):3331024241248833. https://doi.org/10.1177/03331024241248833

Article  PubMed  Google Scholar 

Schrader H, Stovner LJ, Helde G, Sand T, Bovim G (2001) Prophylactic treatment of migraine with angiotensin converting enzyme inhibitor (lisinopril): randomised, placebo controlled, crossover study. BMJ 322(7277):19–22. https://doi.org/10.1136/bmj.322.7277.19

Article  CAS  PubMed  PubMed Central  Google Scholar 

Eigenbrodt AK, Ashina H, Khan S, Diener HC, Mitsikostas DD, Sinclair AJ et al (2021) Diagnosis and management of migraine in ten steps. Nat Rev Neurol 17(8):501–514. https://doi.org/10.1038/s41582-021-00509-5

Article  PubMed  PubMed Central  Google Scholar 

Calabresi P, Galletti F, Rossi C, Sarchielli P, Cupini LM (2007) Antiepileptic drugs in migraine: from clinical aspects to cellular mechanisms. Trends Pharmacol Sci 28:188–195. https://doi.org/10.1016/j.tips.2007.02.005

Article  CAS  PubMed  Google Scholar 

Rogawski MA, Löscher W (2004) The neurobiology of antiepileptic drugs. Nat Rev Neurosci 5:553–564. https://doi.org/10.1038/nrn1430

Article  CAS  PubMed  Google Scholar 

Storer RJ, Goadsby PJ (2004) Topiramate inhibits trigeminovascular neurons in the cat. Cephalalgia 24:1049–1056. https://doi.org/10.1111/j.1468-2982.2004.00767.x

Article  CAS  PubMed  Google Scholar 

Hoffmann J, Akerman S, Goadsby PJ (2014) Efficacy and mechanism of anticonvulsant drugs in migraine. Expert Rev Clin Pharmacol 7:191–201. https://doi.org/10.1586/17512433.2014.885835

Article  CAS  PubMed  Google Scholar 

Raffaelli B, García-Azorín D, Boucherie DM, Amin FM, Deligianni CI, Gil-Gouveia R et al (2023) European Headache Federation (EHF) critical reappraisal and meta-analysis of oral drugs in migraine prevention – part 3: topiramate. J Headache Pain 24(1):134. https://doi.org/10.1186/s10194-023-01671-5

Article  PubMed  PubMed Central  Google Scholar 

Sørensen KV (1988) Valproate: a new drug in migraine prophylaxis. Acta Neurol Scand 78(4):346–348. https://doi.org/10.1111/j.1600-0404.1988.tb03667.x

Article  PubMed  Google Scholar 

Silberstein SD, Collins SD (1999) Safety of divalproex sodium in migraine prophylaxis: an open-label, long-term study. Long-term safety of Depakote in Headache Prophylaxis Study Group. Headache 39(9):633–643. https://doi.org/10.1046/j.1526-4610.1999.3909633.x

Article  CAS  PubMed  Google Scholar 

Linde M, Mulleners WM, Chronicle EP, McCrory DC (2013) Valproate (valproic acid or sodium valproate or a combination of the two) for the prophylaxis of episodic migraine in adults. Cochrane Libr 2013(6):CD010611. https://doi.org/10.1002/14651858.CD010611

Article  Google Scholar 

Sarchielli P, Messina P, Cupini LM, Tedeschi G, Di Piero V, Livrea P et al (2014) Sodium valproate in migraine without aura and medication overuse headache: a randomized controlled trial. Eur Neuropsychopharmacol 24(8):1289–1297. https://doi.org/10.1016/j.euroneuro.2014.03.010

Article  CAS  PubMed  Google Scholar 

Cui XY, Sun SM, Liu J, Wu QY, Zhang JF, Li X (2020) The efficacy and safety of valproate medications for migraine in adults: a meta-analysis. Eur Rev Med Pharmacol Sci 24(10):5734–5741. https://doi.org/10.26355/eurrev_202005_21365

Article  PubMed  Google Scholar 

Marmura MJ, Kumpinsky AS (2018) Refining the Benefit/Risk Profile of anti-epileptic drugs in Headache disorders. CNS Drugs 32(8):735–746. https://doi.org/10.1007/s40263-018-0555-z

Article  PubMed  Google Scholar 

Kanner AM, Bicchi MM (2022) Antiseizure medications for adults with epilepsy. JAMA 327(13):1269–1281. https://doi.org/10.1001/jama.2022.3880

Article  CAS  PubMed  Google Scholar 

Rollo E, Romozzi M, Vollono C, Calabresi P, Geppetti P, Iannone LF (2023) Antiseizure medications for the Prophylaxis of Migraine during the Anti- CGRP drugs era. Curr Neuropharmacol 21(8):1767–1785. https://doi.org/10.2174/1570159X21666221228095256

Article